Tislelizumab with radiation for early nasal lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding a medicine called tislelizumab to radiation works better than radiation alone for newly diagnosed nasal (nasal-type) NK/T-cell lymphoma. If you qualify, it may help control the cancer and improve outcomes by using both treatments together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of extranodal NK/T-cell lymphoma from a tissue (biopsy) sample
- You have never had treatment for this lymphoma before (no prior chemo, radiation, or targeted therapy)
- Your cancer stage is IE or IIE and it is limited to areas like the nose/nasopharynx/oral cavity
- You are age 19 or older, and your overall health score (ECOG) is 0 to 2
- Your scans show at least one measurable tumor area of at least 1.5 cm on CT or PET/CT
- Your blood and organ tests are strong enough (including certain blood count and liver/kidney lab limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining chemotherapy with radiation therapy can work well for people with early-stage NK/T-cell lymphoma that started in the nose or throat. It aims to find a more effective treatment approach with fewer side effects.
This trial tests a combination of an immunotherapy drug (PD-1 antibody, which helps your immune system fight cancer) and radiation therapy for people with early-stage nasal-type NK/T-cell lymphoma. It aims to see if this approach is safe and effective as a first treatment.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests a combination of the immunotherapy drug tislelizumab with two chemotherapy drugs (gemcitabine and peraspartase) for people with newly diagnosed stage I or II NK/T-cell lymphoma. The goal is to see if this combination works well and is safe.
This study tests a new combination of medications for people with early-stage nasal natural killer/T-cell lymphoma. The goal is to see if adding a targeted therapy to standard treatment helps control the disease with manageable side effects.
This study tests whether adding an immunotherapy medicine called tislelizumab to radiation can better control recurrent (coming back) head and neck squamous cell cancer. It is aimed at people whose cancer can’t be fully removed by surgery or can’t be safely removed.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.